Keyword: Valneva

Valneva is seeking a partner for a Lyme disease vaccine development effort it expects will cost $350 million.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth. 

Here's some other vaccine news of note for the week.

Amid a particularly severe flu season, FDA chief Scott Gottlieb said the "holy grail" of vaccines—a shot that fights any strain of virus—is years off.

Here's some other vaccine news of note for the week.

During the two-plus years of Seqirus' existence, the company has worked to hone its portfolio and boost output of next-gen cell culture flu vaccines.

Sanofi's recent loss in C. diff is a win for Pfizer and Valneva, which boast their own late-stage candidates, according to GlobalData.

Here's some other vaccine news of note for the week.

Egg-based production dampened the effects of last year's flu vaccine, a new study says. What's worse, the problem could repeat this year.

Valneva and Emergent BioSolutions will co-develop a Zika candidate slated to enter phase 1 in late 2017 or early 2018.